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BACKGROUND: MicroRNAs (miRNAs) are 19-25-nucleotides regulatory non-protein-coding RNA molecules that regulate the
expressions of a wide variety of genes, including some involved in cancer development. In this study, we investigated the possible role
of miR-143 in colorectal cancer (CRC).
METHODS: Expression levels of human mature miRNAs were examined using real-time PCR-based expression arrays on paired
colorectal carcinomas and adjacent non-cancerous colonic tissues. The downregulation of miR-143 was further evaluated in colon
cancer cell lines and in paired CRC and adjacent non-cancerous colonic tissues by qRT–PCR. Potential targets of miR-143 were
defined. The functional effect of miR-143 and its targets was investigated in human colon cancer cell lines to confirm miRNA–target
association.
RESULTS: Both real-time PCR-based expression arrays and qRT–PCR showed that miR-143 was frequently downregulated in 87.5%
(35 of 40) of colorectal carcinoma tissues compared with their adjacent non-cancerous colonic tissues. Using in silico predictions,
DNA methyltranferase 3A (DNMT3A) was defined as a potential target of miR-143. Restoration of the miR-143 expression in colon
cell lines decreased tumour cell growth and soft-agar colony formation, and downregulated the DNMT3A expression in both mRNA
and protein levels. DNMT3A was shown to be a direct target of miR-143 by luciferase reporter assay. Furthermore, the miR-143
expression was observed to be inversely correlated with DNMT3A mRNA and protein expression in CRC tissues.
CONCLUSION: Our findings suggest that miR-143 regulates DNMT3A in CRC. These findings elucidated a tumour-suppressive role
of miR-143 in the epigenetic aberration of CRC, providing a potential development of miRNA-based targeted approaches for
CRC therapy.
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Colorectal cancer (CRC) is the third most common cancer
worldwide, with an estimated 1 million new cases and half a
million deaths each year (Parkin et al, 2005). Screening for CRC
allows the early diagnosis of the malignancy and reduces the
mortality of the disease (Walsh and Terdiman, 2003). With the
advent of new chemotherapeutic agents, such as angiogenesis
inhibitor and TGF-a inhibitors, there is growing interest to
identify new prognostic biomarkers and therapeutic targets for
this disease.
MicroRNAs are 19-25-nucleotides regulatory non-protein-
coding RNA molecules that regulate the expressions of a wide
variety of genes by sequence-specific base pairing on the
30-untranslated regions (30UTRs) of target mRNA, resulting in
mRNA degradation or inhibition of translation. Patterns of miRNA
expression are meticulously regulated and have important roles in
oncogenesis (He et al, 2005; Lu et al, 2005; Calin and Croce, 2006).
Over the last decade, the number of human genes that are known
to be regulated by miRNAs has increased rapidly (He and Hannon,
2004; Chen, 2005). Studies have shown that profiles of miRNA
expression differ between normal and tumour tissues, which vary
among tumour types (He et al, 2005; Lu et al, 2005; Calin and
Croce, 2006). The downregulation of miRNA subsets implies a
tumour-suppressor function, which is often observed in tumour
development; for example, downregulated let-7 in lung cancer
(Takamizawa et al, 2004; Johnson et al, 2005; Yanaihara et al, 2006)
suppresses Ras (Johnson et al, 2005), deleted or downregulated
miR-15 and miR-16 in chronic lymphocytic leukemia suppress
BCL2 (Calin et al, 2002; Cimmino et al, 2005), and miR-17-5p and
miR-20a control the balance of cell death and proliferation driven
by the proto-oncogene c-Myc (O’Donnell et al, 2005). At present,
more than 690 human miRNAs are annotated in the miRBase
registry (miRBase version 12.0), but most of the genes regulated by
human miRNAs are not well defined.
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Studies have examined miRNA expression profiles of CRC
compared with those of normal colonic mucosa. Two independent
studies reported a general downregulation of miRNAs in tumour
cells in which the expression levels of two miRNAs, miR-145 and
miR-143, were significantly reduced in colorectal tumour cells
(Calin et al, 2004; Gregory and Shiekhattar, 2005). Bandre´s et al
(2006) also evaluated the expression of 156 miRNAs by real-time
PCR in colon cancer cell lines, as well as in paired CRC tissues, and
found that the deregulation of some identified miRNAs in CRC
tumours was consistent with previous studies. In this study,
we aimed at investigating the role of a downregulated miRNA,
miR-143, in CRC.
MATERIALS AND METHODS
Cell culture
Seven human colon cancer cell lines, including 228, CaCO2,
Clone A, HCT116, HT-29, MIP101, and SW480 (American Type
Culture Collection, Manassas, VA, USA), were cultured at 37 1C in
a 10% CO2 atmosphere and maintained routinely in Dulbecco’s
modified Eagle’s Medium (DMEM) supplemented with 10% fetal
bovine serum and 2 mM L-glutamine (Invitrogen, Carlsbad, CA,
USA).
Patient samples
A total of 50 pairs of primary CRCs and their paired non-
cancerous colonic tissues (obtained from 30 patients from Hong
Kong and 20 patients from Germany) were collected. All samples
were collected from patients who underwent a surgical resection of
tumours, either at the Prince of Wales Hospital (Hong Kong) or at
the Charite´ University Hospital (Germany). All patients provided
written informed consent for the use of their tissues. This project
was approved by the Joint CUHK-NTE Clinical Research Ethics
Committee (Hong Kong) and Ethics Committee at the Charite´
University Hospital (Germany).
All tissues had been histologically confirmed to be an
adenocarcinoma of the colon. Tissue samples were collected,
snap-frozen in liquid nitrogen, and stored at 80 1C until further
analysis. For real-time PCR-based miRNA profiling analysis, 10
pairs of CRC and adjacent non-cancerous colonic tissues obtained
from Hong Kong patients were used. The remaining 40 paired
tissue samples were used for quantitative PCR (qPCR) validation.
Real-time PCR-based miRNA array
The miRNA expression profiling was performed using cancer
microRNA qPCR Array with the QuantiMir system (System
Biosciences, Mountain View, CA, USA). This system is a real-time
PCR-based array containing a panel of 95 cancer-related and well-
established mature miRNA assays and the U6 transcript as a
normalisation signal. The kit contains all reagents and primers for
polyadenylation, reverse transcription, and qPCR, except for
reagents for qPCR. In brief, 1 mg of total RNA containing small
RNA extracted from tissue samples was first polyadenylated by
poly(A) polymerase and then reverse transcribed to cDNA using a
mixture of oligo-dT adaptor provided in the kit. The cDNA then
serves as the template for SYBR real-time PCR using Power SYBR
Master Mix (Applied Biosystems, Foster City, CA, USA), using
miRNA-specific primers provided by the manufacturer. SYBR PCR
was performed in an ABI PRISM 7500 Fast Real-time PCR system
(Applied Biosystems). DCt was calculated by subtracting the Ct
values of U6 from the Ct values of the gene of interest. DDCt was
then calculated by subtracting DCt of the control from DCt of
the sample. Fold change of the gene was calculated by the
equation: 2DDCt.
Real-time qPCR
Total RNA containing small RNA was extracted from tissues
and cell lines by TRIzol reagent (Invitrogen), according to the
manufacturer’s instructions. For miRNA qPCR, reverse trans-
cription was performed using the QuantMir RT Kit (System
Biosciences). In brief, 1 mg of RNA containing miRNA was
polyadenylated by poly(A) polymerase and then reverse trans-
cribed to cDNA using oligo-dT primers. The cDNA then serves
as the template for SYBR real-time PCR using SYBR-green PCR
Master Mix (Applied Biosystems). The miR-143-specific forward
primer sequence was 50-TGAGATGAAGCACTGTAGCTC-30 and
was designed on the basis of miRNA sequences obtained from the
miRBase database. Human U6 snRNA was used for normalisation.
For DNA methyltranferase 3A (DNMT3A) mRNA qPCR, cDNA was
synthesised with oligo-dT primers and MMLV reverse trans-
criptase (Promega Corporation, Madison, WI, USA), according to
the manufacturer’s instructions. Gene-specific primers for the
DNMT3A gene were adapted from Xiong et al (2005). mRNA
expression was normalised to b-actin. All real-time qPCR assays
were carried out by the PRISM 7500 Fast Real-time PCR system
(Applied Biosystems). The amplification profile was denatured at
95 1C for 10 min, followed by 40 cycles of 95 1C for 15 s and 60 1C
for 1 min, in which fluorescence was acquired. At the end of the
PCR cycles, melting curve analyses were performed, as well as
electrophoresis of the products on 3.5% agarose gels to validate
the specific generation of the expected PCR product. DCt was
calculated by subtracting the Ct values of U6 or b-actin from the Ct
values of the gene of interest. DDCt was then calculated by
subtracting DCt of the control from DCt of the sample. Fold change
of gene was calculated using the Equation 2DDCt.
Ectopic miR-143 expression
An enforced expression of the miR-143 expression in colon cancer
cells was achieved by transfection with miR-143 precursor
(Ambion, Austin, TX, USA). Cells were plated in culture dishes
or in 24 of 96-well plates for 24 h and transfected with 40 nM
precursor with Lipofectamine 2000 (Invitrogen) for 24 h. Commer-
cially available precursor control (Ambion) was used as a negative
control. Cells were then subjected to further assays or to RNA/
protein extraction.
Cell proliferation assay
Cell proliferation was measured by 3-[4,5-dimethylthiazol-2-yl]-2,
5-diphenyltetrazolium bromide (MTT) assay. Cells were seeded in
a 96-well plate for 24 h, transfected with miR-143 precursor or
DNMT3A siRNA for 24 h, and further cultured in normal medium
for 5 days. Thereafter, the cells were incubated in 0.1 mg ml1 MTT
at 37 1C for 3 h and lysed in DMSO (dimethyl sulfoxide) at room
temperature for 30 min. The absorbance in each well was measured
at 580 nm by a microplate reader.
Anchorage-independent colony formation assay
Soft-agar plates were prepared in 24-well plates with a bottom layer
of 0.6% Noble agar in serum-free DMEM. Cells were trypsinised,
and 500 cells were seeded onto the bottom layer after being mixed
with 0.3% Noble agar in DMEM supplemented with 10% fetal calf
serum. Plates were incubated in a 37-1C incubator for 3 weeks. The
number of colonies was counted after staining with 0.05% crystal
violet for 1 h and washed extensively with 1 PBS.
DNMT3A silencing by siRNA
The sense sequence of a siRNA oligonucleotide targeting DNMT3A
transcript was used as follows: 50-CAGGAGAUGAUGUCCAACCC-30
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(Ambion). Scrambled siRNA was used as a negative control.
Cells were plated in culture dishes or in 96-well plates for 24 h, and
transfected with 40 nM siRNA and Lipofectamine 2000 (Invitrogen)
for 24 h. The cells were then subjected to further assays or to RNA
extraction.
Western blot analysis
Cells were lysed in Lammeli’s lysis buffer, resolved in SDS– PAGE
minigel, and transferred onto an Immobilon-P membrane
(Millipore, Billerica, MA, USA). The membranes were probed with
1 : 1000 diluted primary antibodies against DNMT3A (Epigentek,
Brooklyn, NY, USA) at room temperature for 2 h, washed
extensively with 0.1% Tween-20 in PBS, and incubated with secon-
dary antibodies conjugated with horseradish peroxidase (1 : 10 000
dilution). Signals were visualised with enhanced chemilumines-
cence (Amersham Life Science Inc., Little Chalfont, UK).
Luciferase activity assay
The 30UTR of DNMT3A containing an intact miR-143 recognition
sequence was amplified and the PCR product was sub-cloned into
a pGL3 vector (Promega Corporation) immediately downstream of
the luciferase gene. A pGL3 construct containing DNMT3A 30UTR
with point mutations in seed sequence was synthesised using a
site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA),
according to the manufacturer’s instructions. Cells were
co-transfected with 800 ng pGL3 constructs with or without
miR-143 precursor for 24 h. Each sample was co-transfected
with 0.05mg pRL-CMV plasmid expressing Renilla luciferase to
monitor transfection efficiency (Promega Corporation). Luciferase
activity assay was performed 24 h after transfection using the
dual-luciferase reporter assay system (Promega Corporation).
Relative luciferase activity was normalised with Renilla luciferase
activity.
Statistical analysis
Expressions of miR-143 in paired colorectal tumours and
adjacent non-cancerous tissues were compared by paired t-test.
The difference between the two groups in the MTT assay,
anchorage-independent soft-agar assay, and luciferase reportor
assay was analysed by two-sided Student’s t-test. Data are
expressed as the mean±s.d. from at least three independent
experiments. All P-values are two-sided and a value of o0.05
was considered to be statistically significant. All statistical
calculations were performed using SPSS software (version 13.0,
SPSS, Chicago, IL, USA).
RESULTS
Validation of downregulated miR-143 in CRC tissues and
human colon cancer cell lines
To confirm miR-143 downregulation in CRC, we quantified miR-
143 levels by both real-time PCR-based array and qRT–PCR.
Using real-time PCR-based miRNA expression profiling arrays
containing a panel of 95 cancer-related and well-established
mature miRNAs (including miR-143), we compared the miRNA
profile of pooled RNA samples of primary CRC tumour tissues
from 10 Hong Kong Chinese patients with pooled RNA samples of
their paired adjacent colonic non-cancerous tissues. With a cutoff
value of a three-fold difference, 33 of 95 (35%) miRNAs were
downregulated in CRC. Of the 33 downregulated miRNAs, the
10 most downregulated miRNAs, including miR-125a, miR-125b,
miR-133a, miR-137, miR-143, miR-145, miR-204, miR-215,
miR-26a, and miR-30a-5p, are shown in Table 1. On the basis of
the profiling results, miR-143 is the sixth most downregulated
miRNA, with a seven-fold downregulation. We further validated the
miR-143 expression level in primary CRC tumour tissues from 20
German and 10 Hong Kong patients by qRT–PCR. Our results
showed that miR-143 level was significantly decreased in 27 of
30 (90%) CRC tumour tissues when compared with that in their
adjacent normal tissues (fold change ranging from 3 to 120,
Po0.0001; Wilcoxon’s paired test; Figure 1A). Of the 20 CRC
patients from Germany, 19 (95%) had a miR-143 downregulation.
Of the 10 CRC patients from Hong Kong, 8 (80%) had a miR-143
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Figure 1 The downregulated miR-143 expression in both primary
colorectal cancer tissues and colon cancer cell lines. (A) The relative miR-
143 expression between tumour tissues and their paired adjacent colonic
normal tissues from 30 CRC patients using real-time qPCR. Expression of
miR-143 (Log10 scale at Y axis) was normalised to U6. Statistical difference
was analysed using Wilcoxon’s test, Po0.0001. (B) The relative miR-143
expression in colon cancer cell lines was much lower than that of the three
non-cancerous colonic tissues (N1, N2, and N3).
Table 1 Ten most downregulated miRNAs in colorectal cancer
MicroRNA MirBase No. Fold changes
hsa-miR-30a-5p MIMAT0000087 26.3
hsa-miR-145 MIMAT0000437 25.5
hsa-miR-137 MIMAT0000429 20.6
hsa-miR-133a MIMAT0000427 10.8
hsa-miR-204 MIMAT0000264 8.8
hsa-miR-143 MIMAT0000435 7.0
hsa-miR-215 MIMAT0000271 6.7
hsa-miR-26a MIMAT0000082 6.3
hsa-miR-125b MIMAT0000423 6.1
hsa-miR-125a MIMAT0000443 6.0
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downregulation. The expression of miR-143 was further deter-
mined in a panel of seven human colon cancer cell lines
(HT-29, SW480, 228, CaCO2, Clone A, HCT116, and MCP101).
The expression of miR-143 was markedly lower in all of the seven
colon cancer cell lines than in the three non-tumour colonic tissues
(Figure 1B).
In silico prediction of miR-143 target
Using the algorithms for target gene prediction, including PicTar
(Lall et al, 2006), TargetScan (Lewis et al, 2003), and miRanda
(John et al, 2004), the key enzyme in DNA methylation, DNMT3A,
was identified as one of the potential targets of miR-143. The
predicted binding of miR-143 with DNMT3A 30UTR is illustrated
in Figure 2A. The sequence alignment of human miR-143
with different species of DNMT3A 30UTR was also conserved
(Figure 2B), indicating that DNMT3A is one of the potential direct
targets of miR-143.
Ectopic miR-143 expression inhibits CRC cell growth and
downregulates DNMT3A
Frequent downregulation of miR-143 in colon cancer cell lines and
primary CRC carcinomas implies that miR-143 may have a role in
CRC carcinogenesis. To prove this, the effect of ectopic expression
of miR-143 on cell growth was investigated in two colon cancer cell
lines (228 and SW480). The rationale of using these two cell lines is
that both cell lines expressed a relatively low miR-143 level among
the seven cell lines (Figure 1B). As shown in Figure 3A, the
increased expression of miR-143 by ectopic miR-143 expression
significantly inhibited the growth of 228 and SW480 cells (all
P-values o0.05; Mann–Whitney test). Furthermore, miR-143
expression affected not only tumour cell growth but also malig-
nant transformation phenotypes, as featured by the anchorage-
independent growth of cancer cells in soft-agar medium. The
enforced miR-143 expression significantly reduced the clone
formation efficiency of 228 and SW480 cells in soft agar (all
P-values o0.05; Mann–Whitney test; Figure 3B). These results
provided strong evidence that miR-143 has a role in suppressing
tumour cell growth. Our data indicated that an enforced
miR-143 expression led to a dramatic reduction of DNMT3A
expression at both the mRNA (Po0.05 for 228 cells and Po0.01
for SW480 cells; Mann–Whitney test; Figure 3C) and protein
levels (Figure 3D), suggesting a potential regulation of DNMT3A
by miR-143.
DNMT3A is the direct target miR-143
To further confirm that DNMT3A is the direct target of miR-143, a
segment of the 30UTR of DNMT3A, with or without point
mutations in the seed sequence (Figure 4A), was sub-cloned
downstream of the firefly luciferase reporter. The constructs were
then co-transfected with miR-143 precursor or with pre-miR
control for luciferase activity assays. The relative luciferase activity
of the WT construct of DNMT3A 30UTR in both the colon cancer
cells was significantly reduced in the presence of miR-143 (Po0.05
for 228 cells and Po0.01 for SW480 cells; Mann–Whitney test),
whereas such a suppressive effect of miR-143 on luciferase activity
was not observed in both cells with the MUT construct of
DNMT3A 30UTR (Figure 4B), highlighting a direct and specific
interaction of miR-143 on DNMT3A 30UTR.
Knockdown expression of DNMT3A reduced colon cancer
cell growth
To further establish a link between miR-143 and its downstream
target, DNMT3A, tumour cell proliferation after a siRNA-mediated
knockdown of DNMT3A was examined. Consistent with the
growth inhibitory effect of miRNA-143, cell proliferation of 228
and SW480 cells was significantly reduced by 42 and 44%,
respectively, once the DNMT3A protein expression was effectively
suppressed by siRNA (all P-values o0.05; Mann–Whitney test;
Figure 5A and B).
Expression relationship between miR-143 and DNMT3A in
primary CRC tissues
To confirm the relevance of the expression of DNMT3A and
the relationship between miR-143 and DNMT3A, we assessed
the expressions of miR-143 and DNMT3A mRNA in the seven
colon cancer cell lines and in an independent set of human CRC
tumour tissues and their adjacent colonic tissues from 10 CRC
Hong Kong patients. As shown in Figure 5C, an inverse correlation
of expression between miR-143 and DNMT3A mRNA was
observed in all colon cancer cell lines (r¼0.78, P¼ 0.048;
Spearman’s correlation). Of the CRC patients who were analysed,
80% (8 of 10) simultaneously showed a downregulation of
miR-143 and an upregulation of DNMT3A in tumour tissues
compared with their paired non-cancerous colonic tissues.
We showed that expressions between miR-143 and DNMT3A
mRNA were inversely correlated in all 10 paired CRC and
hsa-miR-143 3′-CTCGA----TGTCACGA---- -------------------------AGTAGAG T- 5′
H. Sapiens 5′ -CGGAGGGCTTTGCCTTGCGAAAAGGGTTGGACATCATCTC -3′
M. Mussculus 5′ -CGGAGGGCTTGGCCTTGC–AAAAGGGTTGGACATCATCTC -3′
R. Norvericus 5′ -CGGAGGGCTTGGCCTTGC–AGAAGGGTTGGACATCATCTC -3′
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Figure 2 In silico prediction of the miR-143 target. (A) Predicted binding of miR-143 (grey) to DNMT3A 30UTR (black). (B) Sequence
alignment of human miR-143 with different species of DNMT3A 30UTR. The seed sequence of miR-143 (bold) perfectly matches with the 30UTR of
DNMT3A.
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adjacent normal tissues (r¼0.59, P¼ 0.0066; Spearman’s corre-
lation; Figure 5D). More importantly, we also found an inverse
correlation of DNMT3A protein and miR-143 in seven paired
CRC tissues (r¼0.71, Po0.05; Spearman’s correlation; Figure 5E
and F).
DISCUSSION
Studies have reported that miR-143 downregulation was common
in various cancers (Michael et al, 2003; Akao et al, 2006, 2007;
Slaby et al, 2007). In this study, we confirmed that miR-143 was
frequently downregulated in CRC tissues than in their correspond-
ing non-cancerous colonic tissues, as illustrated in Figure 1A.
Importantly, we showed for the first time that miR-143 exerted its
function by specifically targeting the gene of a key enzyme,
DNMT3A, involved in DNA methylation. Furthermore, we showed
that miR-143 expression was inversely correlated with DNMT3A
expression in CRC. In addition to a previous study that reported
that the miR-29 family regulated both DNMT3A and DNMT3B in
lung cancer (Fabbri et al, 2007), in this study we showed that
DNMT3A is regulated by miR-143 in CRC. This suggested that
target gene may be regulated by different miRNAs in different
tumours.
Our results obtained from profiling arrays and qPCR validation
were in concordance with previous studies that showed that
miR-143 was downregulated in both colon cancer cell lines and in
more than 85% of CRC patients from Hong Kong (n¼ 30) and
Germany (n¼ 20). These additional data provide evidence that
miR-143 downregulation in CRC commonly occurred in different
ethnic groups. Of the CRC tissues analysed by qPCR analysis,
our data indicated that fold changes of miR-143 expression
between CRC tumours and the corresponding adjacent normal
tissues were not associated with patient characteristics, such as
gender (P¼ 0.563, w2) and tumour stage (P¼ 0.718, w2) (data
not shown). Accordingly, the frequent downregulation of miR-143
in CRC prompted us to believe that miR-143 may have a
tumour-suppressive role in CRC development. By restoring
miR-143 expression in colon cancer cells, we indeed showed that
miR-143 suppressed both cell growth and soft-agar malignant
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Figure 3 The functional effect of ectopic miR-143 expression in 228 and SW480 cells. (A) Ectopic miR-143 expression suppresses cell proliferation in
colon cancer cells. Cells were transfected with miR-143 precursor or control precursor for 24 h. Cell proliferation at 5 days after transfection was assessed by
MTT assay. The miR-143 expression was examined by qPCR (Mann–Whitney test, *Po0.05, **Po0.01). Relative cell proliferation was compared with the
corresponding control inhibitor or precursor (Mann–Whitney test, *Po0.05). (B) Ectopic miR-143 expression reduced the anchorage-independent growth
of cancer cells using soft-agar colony formation assay. Cells were plated in 0.3% noble agar for 3 weeks. The number of colonies was counted after staining
with 0.05% crystal violet (Mann–Whitney test, *Po0.05). Ectopic miR-143 expression reduced both (C) mRNA and (D) protein expression of DNMT3A.
Cells were transfected with miR-143 precursor or with control precursor for 24 h, and then lysed for RNA or protein extraction. DNMT3A mRNA was
detected by real-time qPCR (Mann–Whitney test, *Po0.05, **Po0.01) and protein expression was detected by western blotting with an anti-DNMT3A
antibody. b-Actin was used as a loading control.
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transformation in colon cancer cells, suggesting a tumour-
suppressive role of miR-143.
Our findings indicated that there is a vital molecular link
between miR-143 and DNMT3A. First, we showed that restoration
of miR-143 expression downregulated DNMT3A expression in
both mRNA and protein levels. Second, both loss-of-function
study of DNMT3A by siRNA-mediated knockdown and gain-of-
function study of miR-143 by enforced miR-143 expression
produced a suppressive effect on tumour cell growth, suggesting
that their effects on cellular transformation are inversely
correlated. Third, the inverse correlation between miR-143 and
DNMT3A expression in both colon cancer cell lines and human
CRC tissues further consolidates that downregulation of miR-143
resulting in an upregulation of DNMT3A is significant in CRC
development. More importantly, we also provide evidence from
the luciferase activity assay that DNMT3A is a direct target of miR-
143. Taken together, our findings confirmed that miR-143
regulates DNMT3A expression and has a tumour-suppressive role
in CRC development.
It is well known that DNA methylation has an important role in
oncogenesis. One of the common features in carcinogenesis is the
silencing of tumour suppressor genes by hypermethylation.
Specific changes in DNA methylation patterns in human cancers
could be useful in specific targets for treatment (Jones and Baylin,
2007). Methylation changes to the genome are controlled by DNA
methyltransferases (DNMTs). At present, three catalytically active
DNMTs, namely DNMT1, DNMT3A, and DNMT3B, have been
identified (Jeltsch, 2002). All DNMTs possess de novo methylation
activity, but DNMT1 is inefficient in de novo methylation. During
DNA replication, the DNA methylation pattern is maintained by
DNMT1 after the methylation pattern has been established
(Pradhan et al, 1999). Emerging studies found that the levels of
DNMT1, DNMT3A, and DNMT3B mRNA are reportedly increased
in various malignancies, including colorectal, liver, and gastric
cancers (Eads et al, 1999; Oh et al, 2007; Ding et al, 2008).
Previous studies have shown that gastrointestinal cancer was
characterised by high levels of DNMTs and a low demethyl-
transferase expression (Fang et al, 2006). DNMTs and demethyl-
transferase cooperated with each other, and led to genetic
instability (Geiman et al, 2004) that eventually promoted cancer
progression (Fang et al, 2004). More recently, a study showed that
a high level of DNMT3A protein expression was significantly
associated with a lower overall survival in lung cancer (Fabbri et al,
2007). Thus, patients with a higher DNMT3A expression had
shorter overall survival. Although DNMT1 and DMNT3B are
also important in cancer development, we did not test the effects
of miR-143 on DMNT1 and DMNT3B, because our in silico
predictions did not highlight DNMT1 or DMNT3B as the potential
binding target of miR-143.
Although a high number of oncogenes were predicted to be the
putative target of miR-143 shown in internet algorithms, it has only
been reported that miR-143 regulated the extracellular signal-
regulated kinase 5 (ERK5) expression (Esau et al, 2004; Akao et al,
2006), and downregulation of miR-143 in cancer cells may be directly
involved in carcinogenesis through the activation of the mitogen-
activated protein kinase cascade through ERK5. On the other hand,
the reactivation of tumour suppressor genes by demethylation could
represent another mechanism through which miR-143 exerts its
tumour suppressor function by repressing DNMT3A. Thus, further
study should address the relative contribution of these two
mechanisms to promote anti-oncogenic effect.
Several issues should be addressed in the future. First, as the
number of samples for studies on miR-143 downregulation and
DMNT3A– miR-143 expression correlation is still small, further
validations in large cohorts and in independent studies are
necessary. Second, owing to the heterogeneity of CRC (e.g., high-
level DNA microsatellite instability (MSI-H) vs MSI-low or CpG
island methylator phenotype-high (CIMP-high) vs CIMP-low), it
would be interesting to examine which subsets of CRCs are more
dependent on miR-143 downregulation. Moreover, there may be a
link between CIMP-high and DNMT3A. Third, additional studies
will need to investigate the regulatory mechanism of miR-143
expression so as to better understand why miR-143 is frequently
downregulated in CRC.
In conclusion, miR-143 was frequently downregulated in CRC
and is a potential tumour suppressor miRNA for CRC develop-
ment. miR-143 regulates DNMT3A and might have a part in the
regulation of DNA methylation. These findings may provide a
potential development of miRNA-based targeted approaches for
the treatment of CRC.
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